Technology Bundle ID: TAB-2616

Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling

Request More Info
Licensing Contact:
Primary Inventors: 
Sonja Best (NIAID)
Co-Inventors: 
Kirk Lubick (NIAID), Shelly Robertson (NIAID)
Application: 
Research Materials
Development Status: 
  • Pilot
  • In vitro data available
Institute or Center: 
NIAID

Type I interferons play a critical role in both innate and adaptive immunity through the stimulation of the IFNAR1 which initiates interferon signaling in response to viral and bacterial infections. However, abnormal interferon signaling is associated with human diseases, such as lupus. The present invention discloses six hybridomas that produce mouse monoclonal antibodies specific for the extracellular domain of human IFNAR1. Two of the monoclonal antibodies are able to bind IFNAR1 and reduce interferon signaling. As such, they can be utilized as a research tool for studying the expression of IFNAR1 and the inhibition of IFNAR1 function in humans or possibly as therapeutic reagents for human diseases.

Applications:
  • Research reagents for studying the expression and signaling of IFNAR1.
  • A potential therapeutic reagent.
Advantages:
  • Specific for the extracellular domain of human IFNAR1. Can therefore specifically recognize receptor expressed on the cell surface.
  • Bind IFNAR1 and reduce interferon signaling

Patents

EIR Application

Research Material – Patent protection is not being pursued for this technology.

Publications

Benoit P, et al.
PMID 8423335
Goldman LA, et al.
PMID 10048764

Updated

Aug 22, 2013

Data Source: 
tts